

Date: August 22, 2023

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Intimation of the meeting of the Committee of Directors (Rights Issue) of Piramal Pharma Limited (“Company”) dated August 22, 2023, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”)

Dear Sir/Madam,

This is further to our intimation on the outcome of the meeting of the board of directors of the Company (“**Board**”) dated February 8, 2023, where the issue of fully paid-up equity shares of the Company of face value of ₹10 each (“**Equity Shares**”) was approved by way of a rights issue for an amount not exceeding ₹1,050 crore (“**Rights Issue**”), in accordance with the Companies Act, 2013, as amended and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and other applicable laws and our intimation dated July 27, 2023 regarding the outcome of the meeting of the Committee of Directors (Rights Issue) for approving the various terms of the Rights Issue.

In relation to the aforesaid Rights Issue and pursuant to the finalisation of the basis of allotment of the Rights Issue, in consultation with the designated stock exchange, BSE Limited, the Committee of Directors (Rights Issue) at its meeting held today, i.e., August 22, 2023, *inter alia*, considered and approved the allotment of 12,96,04,598 Equity Shares at a price of ₹81 per Equity Share (including a premium of ₹71 per Equity Share) (“**Allotment**”). This does not include Equity Shares pertaining to persons that are subject to legal proceedings and are accordingly, kept in abeyance.

Accordingly, pursuant to the Allotment, the paid-up equity share capital of the Company has increased from ₹ 1193,31,85,000 to ₹1322,92,30,980.

This intimation is issued in terms of Regulation 30 of the SEBI Listing Regulations.

You are requested to kindly take note of the same.

For Piramal Pharma Limited

Tanya Sanish
Company Secretary